Clinical trial
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell…
NCT00182637 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00182637 |
|---|---|
| Title | Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| Official title | A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL) |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 5 |
| Start date | Jul 1, 2004 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: